Discover
REGN
Regeneron Pharmaceuticals, Inc.
807.17
1 x 806.78
1 x 807.58
bid
ask
-
0.88
0.11%
12:35 PM
timesize
| Ytd | 4.57% | |
| 1y | 47.85% |
802.01
day range
813.63
545.94
52 week range
812.27
| Open | 805.96 | Prev Close | 808.05 | Low | 802.01 | High | 813.63 | Mkt Cap | 83.16B |
| Vol | 235.03K | Avg Vol | 1.02M | EPS | 45.63 | P/E | 17.69 | Forward P/E | 13.05 |
| Beta | 0.22 | Short Ratio | 3.60 | Inst. Own | 94.70% | Dividend | 3.76 | Div Yield | 0.49 |
| Ex Div Date | 08-18 | Earning | 07-30 | 50-d Avg | 660.44 | 200-d Avg | 715.74 | 1yr Est | 833.54 |
| Income Statement | |||
| Total Revenue | 4.29B | ||
| Revenues (USD) | 4.29B | ||
| Cost of Revenue | 576.50M | ||
| Gross Profit | 3.71B | ||
| Operating Expenses | 2.42B | ||
| Research and Development Expense | 1.63B | ||
| Selling, General and Administrative Expense | 662.10M | ||
| Operating Income | 1.29B | ||
| Interest Expense | 11.00M | ||
| Income Tax Expense | 230.90M | ||
| Net Income | 1.30B | ||
| Net Income Common Stock | 1.30B | ||
| Net Income Common Stock (USD) | 1.30B | ||
| Consolidated Income | 1.30B | ||
| Earnings per Basic Share | 12.62 | ||
| Earnings per Basic Share (USD) | 12.62 | ||
| Earnings per Diluted Share | 12.23 | ||
| Dividends per Basic Common Share | 0.94 | ||
| Earning Before Interest & Taxes (EBIT) | 1.54B | ||
| Earning Before Interest & Taxes (USD) | 1.54B | ||
| Weighted Average Shares | 102.80M | ||
| Weighted Average Shares Diluted | 106.00M | ||
| Balance Sheet | |||
| Cash and Equivalents | 2.46B | ||
| Cash and Equivalents (USD) | 2.46B | ||
| Investments | 15.37B | ||
| Investments Current | 5.54B | ||
| Investments Non-Current | 9.83B | ||
| Trade and Non-Trade Receivables | 6.57B | ||
| Current Assets | 18.45B | ||
| Property, Plant & Equipment Net | 5.46B | ||
| Total Assets | 41.73B | ||
| Debt Current | 720.00M | ||
| Total Debt | 2.71B | ||
| Current Liabilities | 5.53B | ||
| Debt Non-Current | 1.99B | ||
| Total Liabilities | 10.02B | ||
| Accumulated Retained Earnings (Deficit) | 37.62B | ||
| Accumulated Other Comprehensive Income | -35.80M | ||
| Shareholders Equity | 31.71B | ||
| Shareholders Equity (USD) | 31.71B | ||
| Assets Non-Current | 23.28B | ||
| Total Debt (USD) | 2.71B | ||
| Deferred Revenue | 905.20M | ||
| Goodwill and Intangible Assets | 1.31B | ||
| Inventory | 3.08B | ||
| Liabilities Non-Current | 4.49B | ||
| Trade and Non-Trade Payables | 1.16B | ||
| Tax Assets | 4.38B | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 123.70M | ||
| Net Cash Flow from Financing | -1.22B | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | -504.60M | ||
| Capital Expenditure | -240.20M | ||
| Issuance (Purchase) of Equity Shares | -1.13B | ||
| Payment of Dividends & Other Cash Distributions | -96.80M | ||
| Net Cash Flow from Investing | -92.70M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | 198.50M | ||
| Net Cash Flow from Operations | 813.00M | ||
| Effect of Exchange Rate Changes on Cash | -300.00K | ||
| Share Based Compensation | 243.00M | ||